Wedbush Maintains Outperform on Larimar Therapeutics, Lowers Price Target to $9

Benzinga · 20h ago
Wedbush analyst Laura Chico maintains Larimar Therapeutics (NASDAQ:LRMR) with a Outperform and lowers the price target from $11 to $9.